Autologous anti-EGFRvIII synNotch receptor-induced anti-EphA2/IL-13Ralpha2 CAR-T cells
Term · Oncology and biomedicine · MLC-T-ONC-011426
A preparation of autologous T lymphocytes engineered to express a synthetic Notch (synNotch) receptor targeting epidermal growth factor receptor variant III (EGFRvIII) that induces the expression of a chimeric antigen receptor (CAR) specific for Ephrin receptor A2 (EphA2) and interleukin-13 receptor alpha 2 (IL13Ra2) upon antigen binding, with potential immunostimulating and antineoplastic activities. After isolation, transduction, expansion and reintroduction into the patient, autologous anti-EGFRvIII synNotch receptor-induced anti-EphA2/IL-13Ralpha2 CAR-T cells target and bind to EGFRvIII-expressing tumor cells, which induces the expression of CAR specific for EphA2 and IL13Ra2. This induces selective toxicity in EphA2-expressing and IL13Ra2-expressing tumor cells locally. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy. IL13Ra2, a cancer-associated receptor, is overexpressed by a variety of tumor cell types; it is associated with increased invasiveness of tumor cells. EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types. EphA2 expression is associated with poor prognosis.
| Identifier | MLC-T-ONC-011426 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | autologous anti-EGFRvIII synNotch receptor induced anti-EphA2/IL-13R alpha2 CAR T cells; autologous anti-EGFRvIII synNotch receptor induced anti-EphA2/IL-13Ra2 CAR T cells; E-SYNC T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011426",
"term": "Autologous anti-EGFRvIII synNotch receptor-induced anti-EphA2/IL-13Ralpha2 CAR-T cells",
"field": "Oncology and biomedicine",
"definition": "A preparation of autologous T lymphocytes engineered to express a synthetic Notch (synNotch) receptor targeting epidermal growth factor receptor variant III (EGFRvIII) that induces the expression of a chimeric antigen receptor (CAR) specific for Ephrin receptor A2 (EphA2) and interleukin-13 receptor alpha 2 (IL13Ra2) upon antigen binding, with potential immunostimulating and antineoplastic activities. After isolation, transduction, expansion and reintroduction into the patient, autologous anti-EGFRvIII synNotch receptor-induced anti-EphA2/IL-13Ralpha2 CAR-T cells target and bind to EGFRvIII-expressing tumor cells, which induces the expression of CAR specific for EphA2 and IL13Ra2. This induces selective toxicity in EphA2-expressing and IL13Ra2-expressing tumor cells locally. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy. IL13Ra2, a cancer-associated receptor, is overexpressed by a variety of tumor cell types; it is associated with increased invasiveness of tumor cells. EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types. EphA2 expression is associated with poor prognosis.",
"synonyms": [
"autologous anti-EGFRvIII synNotch receptor induced anti-EphA2/IL-13R alpha2 CAR T cells",
"autologous anti-EGFRvIII synNotch receptor induced anti-EphA2/IL-13Ra2 CAR T cells",
"E-SYNC T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-anti-egfrviii-synnotch-receptor-induced-anti-epha2-il-13ralpha2-car-t/"
}
Record 2,758 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.